The Comparison of Different Cycles of PD-1 Blockades Combined with Chemotherapy As Neoadjuvant Therapy for Patients with Advanced Gastric Cancer
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.
• Non-bedridden patients aged 18-90 years;
• Histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy;
• Evaluated as resectable advanced gastric cancer via CT, MRI, or laparoscopic exploration;
• No prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy;
• No history of other malignancies within the past 5 years;
• Received at least one cycle of PD-1 inhibitor combined with chemotherapy preoperatively, with no restrictions on the specific PD-1 inhibitor or chemotherapeutic agents;
• Underwent radical gastrectomy after neoadjuvant therapy;
• No severe underlying diseases.